SCHEMBL20970902

SCHEMBL20970902

COc1cc(CCN)cc(OC)c1SC

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 5/20 0.65
▸ HTR2C P28335 3/20 0.63
▸ HTR2B P41595 2/20 0.63
▸ KDM4E B2RXH2 1/20 0.56
▸ ATM Q13315 1/20 0.56
▸ TAAR1 Q96RJ0 7/20 0.53
▸ TSHR P16473 2/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ LMNA P02545 2/20 0.51
▸ GLA P06280 1/20 0.51
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ APEX1 P27695 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ CYP19A1 P11511 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20970986 0.90 HTR2A (0.64) HTR2AHTR2CHTR2BKDM4EATM
SCHEMBL20970927 0.81 HTR2A (0.57) HTR2AHTR2CHTR2BKDM4EATM
SCHEMBL20970855 0.81 HTR2A (0.61) HTR2AHTR2CHTR2BKDM4EATM
SCHEMBL25373111 0.79 HTR2A (1.00) HTR2AHTR2CHTR2BKDM4EATM
SCHEMBL26056124 0.79 HTR2A (0.62) HTR2AHTR2CHTR2BKDM4EATM
SCHEMBL20970884 0.79 HTR2A (0.58) HTR2AHTR2CHTR2BKDM4EATM
SCHEMBL20970922 0.79 HTR2A (0.71) HTR2AHTR2CHTR2BKDM4EATM
SCHEMBL29543975 0.79 HTR2A (0.71) HTR2AHTR2CHTR2BKDM4EATM
SCHEMBL20970984 0.78 HTR2A (0.70) HTR2AHTR2CHTR2BKDM4EATM
Mescaline SCHEMBL34190 0.78 HTR2A (1.00) HTR2AHTR2CHTR2BKDM4EATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108493-A1 COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND CAAMTECH, INC. (US) 2026-04-23 — — US disclosed
US-20260108544-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2026-04-23 — — US disclosed
EP-4720030-A1 ASYMMETRIC PHENYLALKYLAMINES Alexander Shulgin Research Institute, Inc. (US) 2026-04-08 — — EP disclosed
US-20260092034-A1 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME KULEON LLC (US) 2026-04-02 — — US disclosed
US-12570602-B2 Selective serotonin receptor modulators and methods of making and using the same Park City Bio, LLC (US) 2026-03-10 — — US disclosed
US-12564560-B1 Selective serotonin receptor modulators and methods of making and using the same Park City Bio, LLC (US) 2026-03-03 — — US disclosed
US-20260048048-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2026-02-19 — — US disclosed
EP-4673430-A2 PHENYLALKYLAMINE PRODRUGS Alexander Shulgin Research Institute, Inc. (US) 2026-01-07 — — EP disclosed
EP-4673127-A1 DEUTERATED AND FLUORINATED EMPATHOGENS Alexander Shulgin Research Institute, Inc. (US) 2026-01-07 — — EP disclosed
US-20250388529-A1 N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents ALEXANDER SHULGIN RES INSTITUTE INC (US) 2025-12-25 — — US disclosed
US-20220370483-A1 FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION TURTLE BEAR HOLDINGS, LLC 2022-11-24 — — US disclosed
WO-2022236130-A1 FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION TURTLE BEAR HOLDINGS, LLC (US) 2022-11-10 — — WO disclosed
EP-4061359-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH Turtle Bear Holdings, LLC (US) 2022-09-28 — — EP disclosed
WO-2022115798-A2 COMPOSITIONS AND METHODS FOR TREATING MIGRAINE WESANA HEALTH INC. (US) 2022-06-02 — — WO disclosed
WO-2022115796-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS WESANA HEALTH INC. (US) 2022-06-02 — — WO disclosed
US-20220160737-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2022-05-26 — — US disclosed
US-20220125809-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH STAMETS PAUL EDWARD (US) 2022-04-28 — — US disclosed
US-20210361679-A1 COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND CAAMTECH, INC. (US) 2021-11-25 — — US disclosed
US-20210346346-A1 COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND CAAMTECH, INC. (US) 2021-11-11 — — US disclosed
US-20190142851-A1 COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID CAAMTECH, INC. 2019-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190142851-A1 COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID CNR1, CNR2, HTR5A HTR2A 6/4885HTR2C 8/4885HTR2B 11/4885
US-20260092034-A1 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME HTR2C, HTR7, HTR6 HTR2A 6/4885HTR2C 1/4885HTR2B 9/4885
US-20250388529-A1 N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents CNR2, CNR1, HCN3 HTR2A 25/4885HTR2C 6/4885HTR2B 28/4885
US-20210346346-A1 COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND HTR3A, HTR2A, HTR5A HTR2A 2/4885HTR2C 11/4885HTR2B 15/4885
US-20220370483-A1 FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION MAOB, TPSG1, TPSB2 HTR2A 18/4885HTR2C 14/4885HTR2B 11/4885
US-20260048048-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 7/4885HTR2C 4/4885HTR2B 5/4885
US-20220160737-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885
US-20260108493-A1 COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND ADRA2C, ADRB3, ADRA2B HTR2A 19/4885HTR2C 12/4885HTR2B 9/4885
US-20220125809-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885
US-20210361679-A1 COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND HTR3A, HTR2A, HTR5A HTR2A 2/4885HTR2C 11/4885HTR2B 15/4885
US-12570602-B2 Selective serotonin receptor modulators and methods of making and using the same HTR1D, HTR1A, HTR4 HTR2A 14/4885HTR2C 6/4885HTR2B 5/4885
US-12564560-B1 Selective serotonin receptor modulators and methods of making and using the same HTR5A, HTR1A, HTR1D HTR2A 16/4885HTR2C 7/4885HTR2B 14/4885
US-20260108544-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 9/4885HTR2C 5/4885HTR2B 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback